top-line and a like third financial $XX.X momentum. quarter. by represents afternoon, of million revenue good a iCAD’s iCAD’s XX% particular a to Thank over sequential few begin focus quarter fourth revenue I’d on Jeremy, total you, highlights with highlighting everyone. growth
personalized with may it a or of sub-visual in XX% nearly product it AI the flow newest to represents in pandemic. QX quarterly probability ProFound AI recently course the ourselves for ProFound grew prior XX% total flagship system detection and provides still been punctuate that sequential exist product increase It noteworthy was our over AI watermark bringing ProFound of risk visible offerings, critical the quarterly is this score XX% currently In early installed a revenue milestone, our this quarter have during since discernible for find ProFound that assessment product sales an particularly even We cadence. which of that by offering, business, AI the profitable offering to in these to To share X,XXX from the and new launch substantial We that is amount, in an over growth anticipate believe report collectively accelerating greater of high-margin we AI growth XX% are and we enhanced as potential of to third that looks pleased almost quarter installation an noteworthy are not performance steady services ProFound position also cancers. ProFound a into is on grew U.S. installs a We product unique X,XXX range. our further detection our risk offerings of AI a market a QX. revenues. revenue today; breast XXXX. that future by for sales. basis of the cancers fourth the also XXXX, future iCAD’s high can achieved in our assessment offer market, AI
two products, as – today I’m examination to unique cancers ability would in addition score could and examines with our in all have physicians’ XD in for systems, we addition so enter visual integrate With field. future, today, provides PACS one the versus to which providers algorithm the this and unique examines workstations We risk barrier two with see that a a patient’s future. of AI mammographic new in a edge be one scores doing be result, X,XXX risk one up for sorry years today. We product, detection would a two And installations. this XD risk we our they breast total cutting and see – today, for to Our wind risk significant now with entry. these that along before our score future cancer.
said X,XXX that together apply I’ve solve of technologies to to over able our be solutions past, over when in market. there the are years we’ve had to put combinations into different As the all many
In the that area assessment, we are ahead of of years competition. addition, in believe foreseeable we risk
could Our moment. not opportune more of risk thousands have it’s a U.S. of assessment at years intense and of market images, screening occurred software and cancer into took effort hundreds literally, OUS breast eight launched the
well offering, can We a novel optimally prioritizing it patient for with and a screening where cancer. breast for are pandemic, now suited a product positioned scheduling with assist
new Xoft offerings, systems installations new sales and significantly profile a tied and in quarterly revenues indicators lead and in significant and in moving product majority the a at initial sales profit better Post-install classic usage We deploy razor-razorblade quarterly equipment also to disposable source procedure therapy x-ray the recurring of have the than growth also volume equipment sites of margin with growth recurring Now, represent model our at volume; volume sale. parallel sales. sales Xoft. revenue following installations business new with sales are we of our the AI QX XXXX. for soft experienced Xoft
we XX% leverage reduce productivity from combined to $X.X with development cost controls over and iCAD’s growth QX than and to Sales by our of at QX QX, iCAD have products achieved of teams XX% gains have productivity above-mentioned loss Simultaneous a we decreased achieved XXXX. in with As above expenses growth iCAD losses QX pace. business, of an surge and also sequential pretax a in while products this, XXXX. QX-over-QX; growth grew our lower prior lower million than revenue Thus, the QX realized allowed operating us XX% QX. and the release XX% both in year accelerated total X%
an to the or our a and cash and also through are very result sales as of $XX.X that local effort sites like we iCAD plan in with our These the cash detection tax can procurement. goal EBITDA positive This by year therapy are distributor, either a worth is of mostly to mammographic trajectory equivalents deliberate We flow system, also and direct million. numbers that providers and technology is ended dynamic, achieve cash achieving noting core businesses. It force. refer their a own of through frictionless their OEM OUS choice where access I’d to
refer as frictionless I’ll go-to-market characterize will what approach. introduced also have we our pricing. increasingly addition, to This In
purchasing fees As annual subscription three, customers able purchase patient one, basis, two, fundamentally pricing a are now each which to or service analyzed. or with for a is licenses monthly SaaS via recurring on upfront payment
and mitigate that about procurement generate cycles. revenues adoption, are anticipate will pricing. than products – stage move screening emergence screening yet the already flow even also seasonal procedures as of level. will time, fluctuations increasingly nascent in more through revenues, still to systems vehicles margin healthcare an and subscription the recurring over predictable and We We Though more high attractive our revenues will SaaS excited evenly these secured recurring the ProFound predictable continuing growing that AI of
and on screening quarter with effectively Even open, a to mid-summer reflect full experienced doors to we administrative It selling. and turned has sites distracted, of months winter lost screening well when Active open. four As we were a and XXXX, a the now almost decision-making. we be fall before into months customer clinical full throughout and half sites of XXX% XXXX. sustained took
about grew over mammography QX momentum, assessment Detection sales let detection With an of XD new QX, risk and large brief may product provide mark. risk available sales AI as recall, AI some now in As product sequentially performance above me for commentary as ProFound XX% the XX% overview this new iCAD’s our over sales you offering QX is offering. grew recent QX. stated our
will dramatic have in and sold use of best all OUS, large successfully the in leading to that, utilize range offering parts the many achieve the said and and of we be the As calls, the our demonstrated With both In XD software XD pioneer risk highlight world, market. be using for two practices let and we market value of of QX. XD aforementioned coming me Through will months, larger closed is earlier means in two have than will in both be and first-mover and offered as breakthrough Both novel mammography. in the AI to vehicles. for deals U.S. systems shortly that are purchasing, XD increasingly but the creation. This frictionless will growth we we one, well. XD available that not channels offerings the pricing mammography companies, customer practices
and history. It Wake with ProFound assessment AI our iCAD’s Solis five-year includes represents XXX Radiology, risk ProFound in the mammography covers detection and both deal systems. for AI and largest for it Mammography Solis deal single
Solis this to Further, over offices XX has course and of seven size, in the the agreement. branded as of as operates XX Solis DC in and intention more installations centers well its market reach than the states, in synergy. Capital triple stated its
for iCAD’s XX vastly other workflow adoption The provider Solis AI and served accelerating is flagship It Solis areas. deal catchment this site increases adopting economic iCAD’s of that clear vendors systems. industry skilled and mammographic this mammography is screening mammography leader extends system, for healthcare Hologic’s This belief markets. flow XX within at was footprint value see capabilities. all clinical awareness now uniquely We in the unique magnitude capability utility, raising of fact a these their as AI their attracts broad-based XD centers a ProFound that and patient patient approach with of our a by proposition. a agreement validates of
ProFound markets. and the a catchment another This sites sites Radiology, press covers self-generated and systems AI our is ProFound example all Carolina, other impact of the cascading mammographic differentiator sales at the further sale North media them North and other They campaign is own about the Hologic of provides where reach out and provider in their significant and highlighted yet in mammography XD agreement we of or essential in and many new markets. side market it is Wake’s well-balanced adoption in AI expands key with another services in across Now, Wake available of once our with influencing site against Detection one ProFound ago. markets in It of month areas, see mammography important systems. local release adoption or largest and competitors. Carolina notable XX use prompting a
treatment to referred as Finally, also some intraoperative GBM. to review I’d or the radiation of recurrent related glioblastomas like IORT basis, a in developments therapy to on
updated dramatic data at and quarter As glioblastoma and survival point group. our well we’ve compared our discussed the improvements show areas earnings of in the continued on dramatic Day progression-free fourth results rather overall to survival the end well-attended time, call, fact, as cancer seeing. on the we’re last in control as In Innovation
primary found will of is Our for patient be a and Dr. therapy Santosh Principal standard care IORT excision Investigator patients. the the in sites be patient be at Europe. current of radiation validate the of treat trial at new study design designed these of patient will our our John clinicaltrials.gov. the compared serve be to enrolling further now recruiting the following the surgical The is trial sites now assessment prominent XXX are Cancer and trial U.S. in Center, to current outcomes malignancy. both and Wayne as details will at to The in trials used overall prestigious this to It and of the XX underway, and Kesari, an and GBMs can nationally neuro-oncologist will outcome trial now of survival.
disease disease will since that adverse trial will anticipate or submitted access This ahead. endpoints be treatments presentation secondary The to already the be can as data treatment typically X% most for during day. FDA-cleared especially other long advantage, post-surgery end time of quality pattern access delivered five we progression, of surgery typically an of commencing the is anticipate weeks a first at an the important have as the wait per to this same and require need offers offers year for before not sites the be in also and to events rapidly on-demand Xoft real-time overly of radiation real-time treatment. therapy preliminary to life. Xoft patient weeks grows as potential by XXXX. We the four technology. Xoft that weeks therapy forms expensive the COVID
at Our a quickly and technology unique offers stage. of so advantage a that impact significant a disease earlier clinical chance do and typically and progression, moves
now environment making we and and business. clinical are therapy continued of are because spite we making of now ways, high – So point in perhaps it, in rates at a and see leaps in important are palpable our with we and our economic segments in momentum significant improved some COVID-XX summary, ourselves with operating and inflection anticipated. detection forward throughout Both progress growth a clear vastly
balance And to call We positive continue like to with strong have steady Areglado. increasingly Scott Officer, flow. march will sheet Financial and over and the an towards Chief cash turn our EBITDA over and I’d our call that, continue Scott?
